English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The streptococcal fibrinolytic principle (streptokinase) has been demonstrated to be an effective agent, in vivo, in patients as a means of mediating the relatively rapid liquefaction of extravascular fibrin coagulums (1). Streptokinase (referred to in this article as SK) has also been shown to be useful as a therapeutic reagent, by which massive extravascular clots may be eradicated by liquefaction and aspiration (2). These findings have received extensive confirmation. (See Footnote 12 to the list of References.) It is the purpose of this article to describe the results of studies of the intravenous administration of SK into patients. The ultimate objective of the study is directed toward attempting to determine whether or not clots occurring within the vascular system as a result of disease may be subject to

THE INTRAVENOUS INFUSION OF THE STREPTOCOCCAL FIBRINOLYTIC PRINCIPLE (STREPTOKINASE) INTO PATIENTS 1